A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms aboundsqm
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Sep 2017 Interim results (n=343) assessing safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) induction therapy on quality of life (QoL) of patients with squamous (SCC) non-small cell lung cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Interim results (n=334) assessing safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) induction therapy in squamous (SCC) non-small cell lung cancer, were presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 Data from this trial will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, according to a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top